A flexible platform accessible in flexible ways.

We have designed a partnering approach where we offer many entry doors to engage with all kinds of partners: industry, academia, SMEs… To allow to partner with the best, we have built a flexible platform accessible in flexible ways.

Ksilink for industrial partners

You can have access to our in house projects and secure options to increase your R&D pipeline. We may also start a drug discovery program or target discovery program in a strategic collaboration or in a service partnership (see “services”)

Ksilink’s for hospitals & research

We enable scientists to translate the fruit of their early research into tangible assets for the benefit of patients and society. Launching a drug discovery project with Ksilink means you access an enthusiastic, multidisciplinary and open-minded group and network with top level expertise in translational science. Together, we can add substantial value to your project and help you to reach the next milestones and ultimately enter drug development.

At Ksilink, we believe in the power of collaboration.

We work closely with academic partners, leveraging their scientific and domain expertise to obtain patient-derived cell lines. These cell lines form the basis for our drug discovery processes. Our focus is currently on diseases related to the central nervous system. This unique approach allows us to tap into a wealth of knowledge and resources that would otherwise be inaccessible, ensuring that our work is grounded in the latest scientific research.

Once we have identified multiple candidate molecules from a human cell-type specific disease model, we collaborate with partners in the biotech or pharma industry. Our goal is to optimize these molecules into preclinical candidates and ultimately enter clinical trials. This collaborative approach ensures that our findings can be translated into real-world applications, bringing us one step closer to finding cures for diseases. Our unique position as a bridge between academia and industry makes us a valuable partner in drug discovery.